A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2013
At a glance
- Drugs Cediranib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2012 Actual end date changed from 1 Nov 2010 to 1 May 2007 as reported by ClinicalTrials.gov.
- 30 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.